Tresiba® videos for you and your patients

Learn more about Tresiba® by watching videos on its mechanism of protraction, and also on its pharmacokinetics and pharmacodynamics. You can also view videos from our Basal Insights series, where a renowned endocrinologist and expert primary care physician discuss the features of Tresiba®.

Also, introduce your patients to Tresiba® FlexTouch® with helpful videos on Instructions For Use for Tresiba® U-200 and Tresiba® U-100. You may direct your patients to view these instructional videos on Tresiba.com.

Participate in live webcasts on Tresiba® and other related topics


Basal Insights:
An endocrinologist's take on Tresiba® FlexTouch®

Basal Insights: Tresiba® FlexTouch®

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; June 2016.


Basal Insights:
Patient support between office visits

Basal Insights: Patient support


Basal Insights:
A primary care physician talks about once-daily Tresiba®

Basal Insights: Once-daily Tresiba®

Reference:

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; June 2016.


Tresiba® mechanism of protraction (MOP)

Tresiba® MOP

References

  1. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Pharm Res. 2012;29(8):2104-2114.
  2. Haahr H, Heise T. Clin Pharmacokinet. 2014;53(9):787-800.
  3. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; September 2015.
  4. De Rycke A, Mathieu C. Eur Endocrinol. 2011;7(2):84-87. doi:http://doi.org/10.17925/EE.2011.07.02.84.
  5. Seested T, Havelund S, Jonassen IB, Hoeg-Jensen T, Pyke C, Nishimura E. Diabetes. 2012;61(suppl 1):A250 [abstract 980-P].


Introduction to Tresiba®:
Structure and pharmacokinetics / pharmacodynamics

Introduction to Tresiba®: Structure and pharmacokinetics / pharmacodynamics

References

  1. Tresiba [package insert]. Plainsboro, NJ: Novo Nordisk Inc; December 2015.
  2. Jonassen I et al. Pharma Res. 2012;29(8):2104-2114.
  3. Heise T et al. J Diabetes. 2016;8(1):132-138.
  4. Heise T et al. Diabetes Obes Metab. 2012;14(9):859-864.


Tresiba® U-200 FlexTouch® Instructions For Use

Administering Tresiba® U-200 FlexTouch®



Tresiba® U-100 FlexTouch® Instructions For Use

Administering Tresiba® U-100 FlexTouch®


Selected Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening

Indications and Usage

Tresiba® (insulin degludec injection) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Limitations of Use

Tresiba® is not recommended for treating diabetic ketoacidosis or for pediatric patients requiring less than 5 units of Tresiba®.

Important Safety Information

Contraindications

  • Tresiba® is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to Tresiba® or one of its excipients

Warnings and Precautions

  • Never Share a Tresiba® FlexTouch® Pen Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens
  • Monitor blood glucose in all patients treated with insulin. Changes in insulin may affect glycemic control. These changes should be made cautiously and under medical supervision. Adjustments in concomitant oral anti-diabetic treatment may be needed
  • Hypoglycemia is the most common adverse reaction of insulin, including Tresiba®, and may be life-threatening. Increase monitoring with changes to: insulin dose, co-administered glucose lowering medications, meal pattern, physical activity; and in patients with hypoglycemia unawareness or renal or hepatic impairment
  • Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors, always instruct patients to check the insulin label before each injection
  • Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including Tresiba®
  • As with all insulins, Tresiba® use can lead to life-threatening hypokalemia, which then may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated
  • Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Tresiba®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered

Adverse Reactions

  • Adverse reactions commonly associated with Tresiba® are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain

Drug Interactions

  • Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine)

Please click here for Prescribing Information.